Cardiology navigation system maker Stereotaxis plans IPO (initial public offering)
This article was originally published in Clinica
Executive Summary
Stereotaxis, the St Louis, Missouri-based firm that has developed a remote digital control navigation system for cardiovascular procedures in the cath lab, has filed for an initial public offering on Nasdaq. The issue will raise up to $115m, but the company has not yet finalised the terms and timing of the transaction.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.